Recent advances in the development of 225Ac- and 211At-labeled radioligands for radiotheranostics
Analytical Sciences · 2024
DOI: 10.1007/s44211-024-00514-w ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Analytical Sciences, 2024. Verfasst von Masayuki Munekane und 2 weiteren Autor:innen. Beteiligte Einrichtung: Graduate School of Medical Sciences, Kanazawa University, Kakuma-Machi, Kanazawa, Ishikawa, 920-1192, Japan. Hauptthemen laut MEDLINE: Radiopharmaceuticals, Astatine, Actinium, Neoplasms. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 161 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Kanazawa University.
Abstract (Originalsprache)
Radiotheranostics utilizes a set of radioligands incorporating diagnostic or therapeutic radionuclides to achieve both diagnosis and therapy. Imaging probes using diagnostic radionuclides have been used for systemic cancer imaging. Integration of therapeutic radionuclides into the imaging probes serves as potent agents for radionuclide therapy. Among them, targeted alpha therapy (TAT) is a promising next-generation cancer therapy. The α-particles emitted by the radioligands used in TAT result in a high linear energy transfer over a short range, inducing substantial damage to nearby cells surrounding the binding site. Therefore, the key to successful cancer treatment with minimal side effects by TAT depends on the selective delivery of radioligands to their targets. Recently, TAT agents targeting biomolecules highly expressed in various cancer cells, such as sodium/iodide symporter, norepinephrine transporter, somatostatin receptor, α v β 3 integrin, prostate-specific membrane antigen, fibroblast-activation protein, and human epidermal growth factor receptor 2 have been developed and have made remarkable progress toward clinical application. In this review, we focus on two radionuclides, 225 Ac and 211 At, which are expected to have a wide range of applications in TAT. We also introduce recent fundamental and clinical studies of radiopharmaceuticals labeled with these radionuclides. Graphical abstract
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Graduate School of Medical Sciences, Kanazawa University, Kakuma-Machi, Kanazawa, Ishikawa, 920-1192, Japan.
- Graduate School of Medical Sciences, Kanazawa University, Kakuma-Machi, Kanazawa, Ishikawa, 920-1192, Japan. t-fuchi@p.kanazawa-u.ac.jp.
- Graduate School of Medical Sciences, Kanazawa University, Kakuma-Machi, Kanazawa, Ishikawa, 920-1192, Japan. kogawa@p.kanazawa-u.ac.jp.
- Institute for Frontier Science Initiative, Kanazawa University, Kakuma-Machi, Kanazawa, Ishikawa, 920-1192, Japan. kogawa@p.kanazawa-u.ac.jp.
Förderung
- Kanazawa University
Zitieren
APA
Munekane, M., Fuchigami, T., & Ogawa, K. (2024). Recent advances in the development of 225Ac- and 211At-labeled radioligands for radiotheranostics. Analytical Sciences. https://doi.org/10.1007/s44211-024-00514-w
Vancouver
Munekane M, Fuchigami T, Ogawa K. Recent advances in the development of 225Ac- and 211At-labeled radioligands for radiotheranostics. Analytical Sciences. 2024. doi:10.1007/s44211-024-00514-w
BibTeX
@article{Munekane2024,
author = {Munekane, Masayuki and Fuchigami, Takeshi and Ogawa, Kazuma},
title = {Recent advances in the development of 225Ac- and 211At-labeled radioligands for radiotheranostics},
journal = {Analytical Sciences},
year = {2024},
doi = {10.1007/s44211-024-00514-w}
}
EUVIMED